"В настоящее время только один медикамент, рисперидон (risperidone), одобрен Администрацией по контролю продуктов питания и лекарств CША(FDA) для лечения расстройств аутичного спектра (РАС). Возможно, поэтому распространено использование новых, нетрадиционных методов лечения, а так же медикаментов для лечения заболеваний, для которых данное лекарство не было одобрено FDA (off - label). До 74% детей с РАС лечатся этими методами. Тем не менее, доктора часто даже не подозревают об этом." |
|
Ссылки
1. Diagnostic and statistical manual of mental disorders,
4th ed. Washington, DC: American Psychiatric Association;
1994.
2. Baird G, Charman T, Baron-Cohen S, et al. A screening
instrument for autism at 18 months of age: a 6-year
follow-up study. J Am Acad Child Adolesc Psychiatry.
2000;39:694-702.
3. Bertrand J, Mars A, Boyle C, et al. Prevalence of autism
in a United States population: the Brick Township,
New Jersey, investigation. Pediatrics. 2001;108:1155-1161.
4. Chakrabarti S, Fombonne E. Pervasive developmental
disorders in preschool children. JAMA.
2001;285:3093-3099.
5. Rice C. Prevalence of autism spectrum disorders—
autism and developmental disabilities monitoring network,
14 sites, United States, 2002. MMWR. 2007;56:12-28.
6. Muhle R, Trentacoste SV, Rapin I. The genetics of
autism. Pediatrics. 2004;113:e472-e486.
7. Green VA, Pituch KA, Itchon J, et al. Internet survey
of treatments used by parents of children with autism.
Res Dev Disabil. 2006;27:70-84.
8. Aman MG, Lam KS, Collier-Crespin A. Prevalence
and patterns of use of psychoactive medicines among
individuals with autism in the Autism Society of Ohio. J
Autism Dev Disord. 2003;33:527-534.
9. Witwer A, Lecavalier L. Treatment incidence and
patterns in children and adolescents with autism spectrum
disorders. J Child Adolesc Psychopharmacol.
2005;15:671-681.
10. Langworthy-Lam KS, Aman MG, Van Bourgondien
ME. Prevalence and patterns of use of psychoactive
medicines in individuals with autism in the Autism Society
of North Carolina. J Child Adolesc Psychopharmacol.
2002;12:311-321.
11. US Food and Drug Administration. FDA approves
the first drug to treat irritability associated with autism,
risperdal 2006. Available at: http://www.fda.gov/bbs/topics/news/2006/new01485.html. Accessed May 6,
2009.
12. Scott LJ, Dhillon S. Risperidone: a review of its use
in the treatment of irritability associated with autistic
disorder in children and adolescents. Paediatr Drugs.
2007;9:343-354.
13. Rosebush PI, Mazurek MF. Neurologic side effects
in neuroleptic-naive patients treated with haloperidol or
risperidone. Neurology. 1999;52:782-785.
14. Hyman SL, Levy SE. Introduction: novel therapies in
developmental disabilities—hope, reason, and evidence.
Ment Retard Dev Disabil Res Rev. 2005;11:107-109.
15. American Academy of Pediatrics. Counseling
families who choose complementary and alternative
medicine for their child with chronic illness or disability.
Committee on Children With Disabilities. Pediatrics.
2001;107:598-601.
16. Phillips B, Ball C, Sackett D, et al. Oxford Centre
for Evidence-based Medicine Levels of Evidence. 2001.
Available at: http://www.cebm.net/levels_of_evidence.
asp. Accessed May 6, 2009.
17. Sandler AD, Bodfish JW. Placebo effects in autism: lessons
from secretin. J Dev Behav Pediatr. 2000;21:347-350.
18. King BH, Wright DM, Handen BL, et al. Double-blind,
placebo-controlled study of amantadine hydrochloride in
the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658-665.
19. Defining and describing complementary and alternative
medicine. Panel on Definition and Description,
CAM Research Methodology Conference, April 1995.
Altern Ther Health Med. 1997;3:49-57.
20. Loman DG. The use of complementary and alternative
health care practices among children. J Pediatr
Health Care. 2003;17:58-63.
21. Sanders H, Davis MF, Duncan B, et al. Use of complementary
and alternative medical therapies among
children with special health care needs in southern Arizona.
Pediatrics. 2003;111:584-587.
22. Wong HH, Smith RG. Patterns of complementary
and alternative medical therapy use in children diagnosed
with autism spectrum disorders. J Autism Dev
Disord. 2006;36:901-909.
23. Hanson E, Kalish LA, Bunce E, et al. Use of complementary
and alternative medicine among children diagnosed
with autism spectrum disorder. J Autism Dev
Disord. 2007;37:628-636.
24. Wong VC. Use of complementary and alternative
medicine (CAM) in autism spectrum disorder (ASD):
comparison of Chinese and Western culture (part A). J
Autism Dev Disord. 2009;39:454-463.
25. Autism Research Institute. Parent ratings of behavorial
effects of biomedical interventions. ARI Publ
34; February 2008. http://www.autism.com/treatable/form34qr.htm. Accessed May 6, 2009.
26. Levy SE, Mandell DS, Merhar S, et al. Use of complementary
and alternative medicine among children recently
diagnosed with autistic spectrum disorder. J Dev
Behav Pediatr. 2003;24:418-423.
27. Golnik AE, Ireland M. Complementary alternative
medicine for children with autism: a physician survey.
J Autism Dev Disord. 2009;39:996-1005.
28. Liptak GS, Orlando M, Yingling JT, et al. Satisfaction
with primary health care received by families of children
with developmental disabilities. J Pediatr Health Care.
2006;20:245-252.
29. Kemper KJ, O’Connor KG. Pediatricians’ recommendations
for complementary and alternative medical
(CAM) therapies. Ambul Pediatr. 2004;4:482-487.
30. Myers SM, Johnson CP. Management of children
with autism spectrum disorders. Pediatrics.
2007;120:1162-1182.
31. Muskiet FA, Kemperman RF. Folate and long-chain
polyunsaturated fatty acids in psychiatric disease. J Nutr
Biochem. 2006;17:717-727.
32. Fernstrom JD. Can nutrient supplements modify
brain function? Am J Clin Nutr. 2000;71:1669S-1675S.
33. Lakhan SE, Vieira KF. Nutritional therapies for mental
health disorders. Nutr J. 2008;7:2.
34. Carlton RM, Ente G, Blum L, et al. Rational dosages
of nutrients have a prolonged effect on learning disabilities.
Altern Ther Health Med. 2000;6:85-91.
35. Benton D, Roberts G. Effect of vitamin and mineral
supplementation on intelligence of a sample of schoolchildren.
Lancet. 1988;1:140-143.
36. Osendarp SJ, Baghurst KI, Bryan J, et al. Effect of
a 12-mo micronutrient intervention on learning and
memory in well-nourished and marginally nourished
school-aged children: 2 parallel, randomized, placebocontrolled
studies in Australia and Indonesia. Am J Clin
Nutr. 2007;86:1082-1093.
37. Haskell CF, Scholey AB, Jackson PA, et al. Cognitive
and mood effects in healthy children during 12 weeks’
supplementation with multi-vitamin/minerals. Br J
Nutr. 2008;100:1086-1096.
38. MacLellan D, Taylor J, Wood K. Food intake and academic
performance among adolescents. Can J Diet Pract
Res. 2008;69:141-144.
39. Schreck KA, Williams K, Smith AF. A comparison
of eating behaviors between children with and without
autism. J Autism Dev Disord. 2004;34:433-438.
40. Herndon AC, DiGuiseppi C, Johnson SL, et al. Does
nutritional intake differ between children with autism
spectrum disorders and children with typical development?
J Autism Dev Disord. 2009;39:212-222.
41. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric
disorders: evidence base and therapeutic implications.
Int J Neuropsychopharmacol. 2008;11:851-876.
42. Tsaluchidu S, Cocchi M, Tonello L, et al. Fatty acids
and oxidative stress in psychiatric disorders. BMC Psychiatry.
2008;8(suppl 1):S5.
43. Yorbik O, Sayal A, Akay C, et al. Investigation of antioxidant
enzymes in children with autistic disorder. Prostaglandins
Leukot Essent Fatty Acids. 2002;67:341-343.
44. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype
and related genotypes are associated with
oxidative stress in children with autism. Am J Med Genet
B Neuropsychiatr Genet. 2006;141:947-956.
45. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers
of increased oxidative stress and impaired
methylation capacity in children with autism. Am J Clin
Nutr. 2004;80:1611-1617.
46. Chauhan A, Chauhan V, Brown WT, et al. Oxidative
stress in autism: increased lipid peroxidation and reduced
serum levels of ceruloplasmin and transferrin—
the antioxidant proteins. Life Sci. 2004;75:2539-2549.
47. Chauhan A, Chauhan V. Oxidative stress in autism.
Pathophysiology. 2006;13:171-181.
48. Sperner-Unterweger B. Immunological aetiology of
major psychiatric disorders: evidence and therapeutic
implications. Drugs. 2005;65:1493-1520.
49. Pardo CA, Vargas DL, Zimmerman AW. Immunity,
neuroglia and neuroinflammation in autism. Int Rev
Psychiatry. 2005;17:485-495.
50. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial
activation and neuroinflammation in the brain of
patients with autism. Ann Neurol. 2005;57:67-81.
51. Chez MG, Dowling T, Patel PB, et al. Elevation of
tumor necrosis factor-alpha in cerebrospinal fluid of autistic
children. Pediatr Neurol. 2007;36:361-365.
52. Connolly AM, Chez MG, Pestronk A, et al. Serum
autoantibodies to brain in Landau-Kleffner variant, autism,
and other neurologic disorders. J Pediatr. 1999;134:
607-613.
53. Connolly AM, Chez M, Streif EM, et al. Brainderived
neurotrophic factor and autoantibodies to neural
antigens in sera of children with autistic spectrum
disorders, Landau-Kleffner syndrome, and epilepsy.
Biol Psychiatry. 2006;59:354-363.
54. Torrente F, Ashwood P, Day R, et al. Small intestinal
enteropathy with epithelial IgG and complement deposition
in children with regressive autism. Mol Psychiatry.
2002;7:375-382, 334.
55. Furlano RI, Anthony A, Day R, et al. Colonic CD8
and gamma delta T-cell infiltration with epithelial damage
in children with autism. J Pediatr. 2001;138:366-372.
56. Ashwood P, Anthony A, Pellicer AA, et al. Intestinal
lymphocyte populations in children with regressive autism:
evidence for extensive mucosal immunopathology.
J Clin Immunol. 2003;23:504-517.
57. Balzola F, Daniela C, Repici A, et al. Autistic enterocolitis:
confirmation of a new inflammatory bowel disease
in an Italian cohort of patients. Gastroenterology.
2005;128:A303.
58. Horvath K, Papadimitriou JC, Rabsztyn A, et al.
Gastrointestinal abnormalities in children with autistic
disorder. J Pediatr. 1999;135:559-563.
59. Valicenti-McDermott M, McVicar K, Rapin I, et al.
Frequency of gastrointestinal symptoms in children with
autistic spectrum disorders and association with family
history of autoimmune disease. J Dev Behav Pediatr.
2006;27:S128-S136.
60. Horvath K, Perman JA. Autism and gastrointestinal
symptoms. Curr Gastroenterol Rep. 2002;4:251-258.
61. Finegold SM, Molitoris D, Song Y, et al. Gastrointestinal
microflora studies in late-onset autism. Clin Infect
Dis. 2002;35:S6-S16.
62. Song Y, Liu C, Finegold SM. Real-time PCR quantitation
of clostridia in feces of autistic children. Appl Environ
Microbiol. 2004;70:6459-6465.
63. Parracho HM, Bingham MO, Gibson GR, et al. Differences
between the gut microflora of children with
autistic spectrum disorders and that of healthy children.
J Med Microbiol. 2005;54:987-991.
64. Jyonouchi H, Geng L, Ruby A, et al. Evaluation of
an association between gastrointestinal symptoms and
cytokine production against common dietary proteins
in children with autism spectrum disorders. J Pediatr.
2005;146:605-610.
65. Buie TM. Gastroesophageal reflux in children with
autism: how do children present and can one test these
children? J Pediatr Gastroenterol Nutr. 2005;41:505.
66. Levy SE, Hyman SL. Novel treatments for autistic
spectrum disorders. Ment Retard Dev Disabil Res Rev.
2005;11:131-142.
67. Nir I, Meir D, Zilber N, et al. Brief report: circadian
melatonin, thyroid-stimulating hormone, prolactin, and
cortisol levels in serum of young adults with autism. J
Autism Dev Disord. 1995;25:641-654.
68. Kulman G, Lissoni P, Rovelli F, et al. Evidence of pineal
endocrine hypofunction in autistic children. Neuro
Endocrinol Lett. 2000;21:31-34.
69. Tordjman S, Anderson GM, Pichard N, et al. Nocturnal
excretion of 6-sulphatoxymelatonin in children
and adolescents with autistic disorder. Biol Psychiatry.
2005;57:134-138.
70. Melke J, Goubran Botros H, Chaste P, et al. Abnormal
melatonin synthesis in autism spectrum disorders.
Mol Psychiatry. 2008;13:90-98.
71. Jan JE, O’Donnell ME. Use of melatonin in the
treatment of paediatric sleep disorders. J Pineal Res.
1996;21:193-199.
72. Hayashi E. Effect of melatonin on sleep-wake
rhythm: the sleep diary of an autistic male. Psychiatry
Clin Neurosci. 2000;54:383-384.
73. Ishizaki A, Sugama M, Takeuchi N. [Usefulness of
melatonin for developmental sleep and emotional/behavior
disorders—studies of melatonin trial on 50 patients
with developmental disorders] [In Japanese]. No
To Hattatsu. 1999;31:428-437.
74. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, et
al. Effectiveness of melatonin in the treatment of sleep
disturbances in children with Asperger disorder. J Child
Adolesc Psychopharmacol. 2003;13:83-95.
75. Giannotti F, Cortesi F, Cerquiglini A, et al. An openlabel
study of controlled-release melatonin in treatment
of sleep disorders in children with autism. J Autism Dev
Disord. 2006;36:741-752.
76. Andersen IM, Kaczmarska J, McGrew SG, et al. Melatonin
for insomnia in children with autism spectrum
disorders. J Child Neurol. 2008;23:482-485.
77. Wasdell MB, Jan JE, Bomben MM, et al. A randomized,
placebo-controlled trial of controlled release melatonin
treatment of delayed sleep phase syndrome and
impaired sleep maintenance in children with neurodevelopmental
disabilities. J Pineal Res. 2008;44:57-64.
78. Garstang J, Wallis M. Randomized controlled trial of
melatonin for children with autistic spectrum disorders
and sleep problems. Child Care Health Dev. 2006;32:
585-589.
79. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy
of melatonin for sleep problems in children with autism,
fragile X syndrome, or autism and fragile X syndrome. J
Clin Sleep Med. 2009;5:145-150.
80. Filipek PA, Juranek J, Nguyen MT, et al. Relative
carnitine deficiency in autism. J Autism Dev Disord.
2004;34:615-623.
81. Ellaway CJ, Peat J, Williams K, et al. Medium-term
open label trial of L-carnitine in Rett syndrome. Brain
Dev. 2001;23 suppl 1:S85-S89.
82. Ellaway C, Williams K, Leonard H, et al. Rett syndrome:
randomized controlled trial of L-carnitine. J
Child Neurol. 1999;14:162-167.
83. Tani Y, Fernell E, Watanabe Y, et al. Decrease in 6R-
5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid
of autistic patients. Neurosci Lett. 1994;181:169-172.
84. Komori H, Matsuishi T, Yamada S, et al. Cerebrospinal
fluid biopterin and biogenic amine metabolites during
oral R-THBP therapy for infantile autism. J Autism
Dev Disord. 1995;25:183-193.
85. Nagahata M, Kazamaturi H, Nuruse H, et al. Clinical evaluation of apropterin hydrochloride (R-THBP) on
infantile autism: a multicenter cooperative study. In: Naruse
H, Ornitz EM, eds. Neurobiology of infantile autism.
Proceedings of the International Symposium on Neurobiology
of Infantile Autism; Nov 10-11, 1990; Tokyo, Japan.
Amsterdam: Elsevier Science Ltd; 1992: 351-354.
86. Fernell E, Watanabe Y, Adolfsson I, et al. Possible
effects of tetrahydrobiopterin treatment in six
children with autism—clinical and positron emission
tomography data: a pilot study. Dev Med Child Neurol.
1997;39:313-318.
87. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin
in the treatment of children with autistic
disorder: a double-blind placebo-controlled crossover
study. J Clin Psychopharmacol. 2005;25:485-489.
88. Nakane Y, Naruse H, Takesada M, et al. Clinical effect
of R-THBP on infantile autism. In: Naruse H, Ornitz
EM, eds. Neurobiology of infantile autism. Proceedings
of the International Symposium on Neurobiology of Infantile
Autism; Nov 10-11, 1990; Tokyo, Japan. Amsterdam:
Elsevier Science Ltd; 1992: 337-350.
89. Monks G, Juracek L, Weigand D, et al. A case of scurvy
in an autistic boy. J Drugs Dermatol. 2002;1:67-69.
90. Duggan CP, Westra SJ, Rosenberg AE. Case records
of the Massachusetts General Hospital. Case 23-2007. A
9-year-old boy with bone pain, rash, and gingival hypertrophy.
N Engl J Med. 2007;357:392-400.
91. Dolske MC, Spollen J, McKay S, et al. A preliminary
trial of ascorbic acid as supplemental therapy for
autism. Prog Neuropsychopharmacol Biol Psychiatry.
1993;17:765-774.
92. Chez MG, Buchanan CP, Aimonovitch MC, et al.
Double-blind, placebo-controlled study of L-carnosine
supplementation in children with autistic spectrum disorders.
J Child Neurol. 2002;17:833-837.
93. Adams JB, Holloway C. Pilot study of a moderate
dose multivitamin/mineral supplement for children
with autistic spectrum disorder. J Altern Complement
Med. 2004;10:1033-1039.
94. Paczynski M. Piracetam: a novel therapy for autism?
J Autism Dev Disord. 1997;27:628-630.
95. Akhondzadeh S, Tajdar H, Mohammadi MR, et al.
A double-blind placebo controlled trial of piracetam
added to risperidone in patients with autistic disorder.
Child Psychiatry Hum Dev. 2008;39:237-245.
96. Richardson AJ, Calvin CM, Clisby C, et al. Fatty acid
deficiency signs predict the severity of reading and related
difficulties in dyslexic children. Prostaglandins
Leukot Essent Fatty Acids. 2000;63:69-74.
97. Richardson AJ. Omega-3 fatty acids in ADHD and
related neurodevelopmental disorders. Int Rev Psychiatry.
2006;18:155-172.
98. Richardson AJ. Long-chain polyunsaturated fatty
acids in childhood developmental and psychiatric disorders.
Lipids. 2004;39:1215-1222.
99. Stevens LJ, Zentall SS, Abate ML, et al. Omega-3 fatty
acids in boys with behavior, learning, and health problems.
Physiol Behav. 1996;59:915-920.
100. Vancassel S, Durand G, Barthelemy C, et al. Plasma
fatty acid levels in autistic children. Prostaglandins Leukot
Essent Fatty Acids. 2001;65:1-7.
101. Bell JG, MacKinlay EE, Dick JR, et al. Essential
fatty acids and phospholipase A2 in autistic spectrum
disorders. Prostaglandins Leukot Essent Fatty Acids.
2004;71:201-204.
102. Sliwinski S, Croonenberghs J, Christophe A, et al.
Polyunsaturated fatty acids: do they have a role in the
pathophysiology of autism? Neuro Endocrinol Lett.
2006;27:465-471.
103. Schultz ST, Klonoff-Cohen HS, Wingard DL, et al.
Breastfeeding, infant formula supplementation, and autistic
disorder: the results of a parent survey. Int Breastfeed
J. 2006;1:16.
104. Johnson SM, Hollander E. Evidence that eicosapentaenoic
acid is effective in treating autism. J Clin Psychiatry.
2003;64:848-849.
105. Patrick L, Salik R. The effect of essential fatty acid
supplementation on language development and learning
skills in autism and Asperger’s syndrome. Autism
Asperger’s Digest. 2005;Jan/Feb:36-37.
106. Politi P, Cena H, Comelli M, et al. Behavioral effects
of omega-3 fatty acid supplementation in young adults
with severe autism: an open label study. Arch Med Res.
2008;39:682-685.
107. Meguid NA, Atta HM, Gouda AS, et al. Role of polyunsaturated
fatty acids in the management of Egyptian
children with autism. Clin Biochem. 2008;41:1044-1048.
108. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism:
a double-blind randomized, placebo-controlled pilot
study. Biol Psychiatry. 2007;61:551-553.
109. Bent S, Bertoglio K, Hendren RL. Omega-3 fatty acids
for autistic spectrum disorder: a systematic review. J
Autism Dev Disord. 2009; 39:1145-1154.
110. Adams JB, George F, Audhya T. Abnormally high
plasma levels of vitamin B6 in children with autism not
taking supplements compared to controls not taking
supplements. J Altern Complement Med. 2006;12:59-63.
111. Strambi M, Longini M, Hayek J, et al. Magnesium
profile in autism. Biol Trace Elem Res. 2006;109:97-104.
112. Bonish VE. Experiences with vitamin B6 with braindamaged
children with autistic syndrome. Proxis der
Kinderpsychologie. 1968;8:308-310.
113. Rimland B. An orthomolecular study of psychotic
children. Orthomolecular Psychiatry. 1974;3:371-377.
114. Barthelemy C, Martineau J, Bruneau N, et al. [Clinical
(behavior scale items), electrophysiologic (conditioned
evoked potentials) and biochemical (urinary homovanillic
acid) markers in infantile autism] [In French].
Encephale. 1985;11:101-106.
115. Lelord G, Callaway E, Muh JP, et al. [Modifications in
urinary homovanillic acid after ingestion of vitamin B6;
functional study in autistic children (author’s transl)] [In
French]. Rev Neurol (Paris). 1978;134:797-801.
116. Martineau J, Garreau B, Barthelemy C, et al. Effects
of vitamin B6 on averaged evoked potentials in infantile
autism. Biol Psychiatry. 1981;16:627-641.
117. Martineau J, Barthelemy C, Cheliakine C, et al. Brief
report: an open middle-term study of combined vitamin
B6-magnesium in a subgroup of autistic children selected
on their sensitivity to this treatment. J Autism Dev
Disord. 1988;18:435-447.
118. Martineau J, Barthelemy C, Roux S, et al. Electrophysiological
effects of fenfluramine or combined vitamin
B6 and magnesium on children with autistic behaviour.
Dev Med Child Neurol. 1989;31:721-727.
119. Menage P, Thibault G, Barthelemy C, et al. CD 4+CD 45 RA+ T lymphocyte deficiency in autistic children:
effect of a pyridoxine-magnesium treatment. Brain Dysfunct.
1992;5:326-333.
120. Barthelemy C, Garreau B, Leddet I, et al. [Biological
and clinical effects of oral magnesium and associated
magnesium-vitamin B6 administration on certain disorders
observed in infantile autism (author’s transl)] [In
French]. Therapie. 1980;35:627-632.
121. Barthelemy C, Garreau B, Leddet I. Behavioral and
biological effects of oral magnesium, vitamin B6 and
combined magnesium–vitamin B6 administration in
autistic children. Magnes Bull. 1981;2:150-153.
122. Jonas C, Etienne T, Barthelemy C, et al. [Clinical and
biochemical value of Magnesium + vitamin B6 combination
in the treatment of residual autism in adults] [In
French]. Therapie. 1984;39:661-669.
123. Martineau J, Barthelemy C, Garreau B, et al. Vitamin
B6, magnesium, and combined B6-Mg: therapeutic effects
in childhood autism. Biol Psychiatry. 1985;20:467-478.
124. Lelord G, Muh JP, Barthelemy C, et al. Effects of pyridoxine
and magnesium on autistic symptoms—initial
observations. J Autism Dev Disord. 1981;11:219-230.
125. Lelord G, Callaway E, Muh JP. Clinical and biological
effects of high doses of vitamin B6 and magnesium on
autistic children. Acta Vitaminol Enzymol. 1982;4:27-44.
126. Rimland B, Callaway E, Dreyfus P. The effect of high
doses of vitamin B6 on autistic children: a double-blind
crossover study. Am J Psychiatry. 1978;135:472-475.
127. Tolbert L, Haigler T, Waits MM, et al. Brief report:
lack of response in an autistic population to a low dose
clinical trial of pyridoxine plus magnesium. J Autism Dev
Disord. 1993;23:193-199.
128. Findling RL, Maxwell K, Scotese-Wojtila L, et al.
High-dose pyridoxine and magnesium administration
in children with autistic disorder: an absence of salutary
effects in a double-blind, placebo-controlled study. J Autism
Dev Disord. 1997;27:467-478.
129. Kuriyama S, Kamiyama M, Watanabe M, et al. Pyridoxine
treatment in a subgroup of children with pervasive
developmental disorders. Dev Med Child Neurol.
2002;44:284-286.
130. Nye C, Brice A. Combined vitamin B6-magnesium
treatment in autism spectrum disorder. Cochrane Database
Syst Rev. 2005;(4):CD003497.
131. Mousain-Bosc M, Roche M, Polge A, et al. Improvement
of neurobehavioral disorders in children supplemented
with magnesium-vitamin B6. II. Pervasive developmental
disorder-autism. Magnes Res. 2006;19:53-62.
132. McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia
in a child treated with megavitamin/megamineral
therapy. Pediatrics. 2000;105:E18.
133. Wakefield AJ, Murch SH, Anthony A, et al. Ileallymphoid-nodular hyperplasia, non-specific colitis, and
pervasive developmental disorder in children. Lancet.
1998;351:637-641.
134. Lowe TL, Cohen DJ, Miller S, et al. Folic acid and B12
in autism and neuropsychiatric disturbances of childhood.
J Am Acad Child Psychiatry. 1981;20:104-111.
135. Gillberg C, Wahlstrom J, Johansson R, et al. Folic
acid as an adjunct in the treatment of children with the
autism fragile-X syndrome (AFRAX). Dev Med Child
Neurol. 1986;28:624-627.
136. Nakano K, Noda N, Tachikawa E, et al. A preliminary
study of methylcobalamin therapy in autism. Journal of
Tokyo Women’s Medical University. 2005;75:64-69.
137. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin
and folinic acid treatment on glutathione redox
status in children with autism. Am J Clin Nutr. 2009;89:1-6.
138. Moretti P, Peters SU, Del Gaudio D, et al. Brief report:
autistic symptoms, developmental regression, mental
retardation, epilepsy, and dyskinesias in CNS folate deficiency.
J Autism Dev Disord. 2008;38:1170-1177.
139. Moretti P, Sahoo T, Hyland K, et al. Cerebral folate
deficiency with developmental delay, autism, and response
to folinic acid. Neurology. 2005;64:1088-1090.
140. Ramaekers VT, Blau N, Sequeira JM, et al. Folate
receptor autoimmunity and cerebral folate deficiency in
low-functioning autism with neurological deficits. Neuropediatrics.
2007;38:276-281.
141. Ramaekers VT, Sequeira JM, Blau N, et al. A milkfree
diet downregulates folate receptor autoimmunity
in cerebral folate deficiency syndrome. Dev Med Child
Neurol. 2008;50:346-352.
142. Niederhofer H. First preliminary results of an observation
of Ginkgo Biloba treating patients with autistic disorder.
Phytother Res. 2009 Mar 9. [E-pub ahead of print.]
143. Levine J, Aviram A, Holan A, et al. Inositol treatment
of autism. J Neural Transm. 1997;104:307-310.
144. Lozoff B, Beard J, Connor J, et al. Long-lasting neural
and behavioral effects of iron deficiency in infancy. Nutr
Rev. 2006;64:S34-43; discussion S72-91.
145. Halterman JS, Kaczorowski JM, Aligne CA, et al. Iron
deficiency and cognitive achievement among schoolaged
children and adolescents in the United States. Pediatrics.
2001;107:1381-1386.
146. Bruner AB, Joffe A, Duggan AK, et al. Randomised
study of cognitive effects of iron supplementation in
non-anaemic iron-deficient adolescent girls. Lancet.
1996;348:992-996.
147. Latif A, Heinz P, Cook R. Iron deficiency in autism
and Asperger syndrome. Autism. 2002;6:103-114.
148. Dosman CF, Drmic IE, Brian JA, et al. Ferritin as
an indicator of suspected iron deficiency in children
with autism spectrum disorder: prevalence of low serum
ferritin concentration. Dev Med Child Neurol.
2006;48:1008-1009.
149. Cornish E. A balanced approach towards healthy
eating in autism. Journal of Human Nutrition and Dietetics.
1998;11:501-509.
150. Dosman CF, Brian JA, Drmic IE, et al. Children with
autism: effect of iron supplementation on sleep and ferritin.
Pediatr Neurol. 2007;36:152-158.
151. Sandler RH, Finegold SM, Bolte ER, et al. Short-term
benefit from oral vancomycin treatment of regressiveonset
autism. J Child Neurol. 2000;15:429-435.
152. Brudnak MA, Rimland B, Kerry RE, et al. Enzymebased
therapy for autism spectrum disorders—is it
worth another look? Med Hypotheses. 2002;58:422-428.
153. Brudnak MA. Probiotics as an adjuvant to detoxification
protocols. Med Hypotheses. 2002;58:382-385.
154. Blades M. Autism: an interesting dietary case history.
Nutrition and Food Science. 2000;30:137-140.
155. Niederhofer H. St John’s Wort treating patients with
autistic disorder. Phytother Res. 2009;Mar 9[Epub ahead
of print].
156. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine
in patients with autistic disorder. J Autism Dev
Disord. 1999;29:191-194.
157. Kern JK, Miller VS, Cauller PL, et al. Effectiveness of
N,N-dimethylglycine in autism and pervasive developmental
disorder. J Child Neurol. 2001;16:169-173.
158. McDougle CJ, Naylor ST, Cohen DJ, et al. Effects of
tryptophan depletion in drug-free adults with autistic
disorder. Arch Gen Psychiatry. 1996;53:993-1000.
159. Sverd J, Kupietz SS, Winsberg BG, et al. Effects of L-5-hydroxytryptophan in autistic children. J Autism Child
Schizophr. 1978;8:171-180.
160. Cannell JJ. Autism and vitamin D. Med Hypotheses.
2008;70:750-759.
161. Stewart C, Latif A. Symptomatic nutritional rickets
in a teenager with autistic spectrum disorder. Child Care
Health Dev. 2008;34:276-278.
162. Clark JH, Rhoden DK, Turner DS. Symptomatic
vitamin A and D deficiencies in an eight-year-old with
autism. JPEN J Parenter Enteral Nutr. 1993;17:284-286.
163. Steinemann TL, Christiansen SP. Vitamin A deficiency
and xerophthalmia in an autistic child. Arch
Ophthalmol. 1998;116:392-393.
164. Uyanik O, Dogangun B, Kayaalp L, et al. Food faddism
causing vision loss in an autistic child. Child Care
Health Dev. 2006;32:601-602.
165. Megson MN. Is autism a G-alpha protein defect
reversible with natural vitamin A? Med Hypotheses.
2000;54:979-983.
166. Shaywitz BA, Siegel NJ, Pearson HA. Megavitamins
for minimal brain dysfunction. A potentially dangerous
therapy. JAMA. 1977;238:1749-1750.
167. Kimmoun A, Leheup B, Feillet F, et al. [Hypercalcemia
revealing iatrogenic hypervitaminosis A in a
child with autistic troubles] [In French]. Arch Pediatr.
2008;15:29-32.
168. Jory J, McGinnis WR. Red-cell trace minerals in children
with autism. Am J Biochem Biotech. 2008;4:101-
104.
169. Pfeiffer CC, Braverman ER. Zinc, the brain and behavior.
Biol Psychiatry. 1982;17:513-532.
170. Yorbik O, Olgun A, Kirmizigul P, et al. [Plasma zinc
and copper levels in boys with oppositional defiant disorder]
[In Turkish]. Turk Psikiyatri Derg. 2004;15:276-281.
171. Jackson MJ, Garrod PJ. Plasma zinc, copper, and
amino acid levels in the blood of autistic children. J Autism
Child Schizophr. 1978;8:203-208.
172. Yorbik O, Akay C, Sayal A, et al. Zinc status in autistic
children. J Trace Elem Exp Med. 2004;17:101-107.
173. Panksepp J. A neurochemical theory of autism.
Trends Neurosci. 1979;2:174-177.
174. Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies
to neuron-specific antigens in children with autism:
possible cross-reaction with encephalitogenic proteins
from milk, Chlamydia pneumoniae and Streptococcus
group A. J Neuroimmunol. 2002;129:168-177.
175. Vojdani A, Pangborn JB, Vojdani E, et al. Infections,
toxic chemicals and dietary peptides binding to lymphocyte
receptors and tissue enzymes are major instigators
of autoimmunity in autism. Int J Immunopathol Pharmacol.
2003;16:189-199.
176. Vojdani A, O’Bryan T, Green JA, et al. Immune response
to dietary proteins, gliadin and cerebellar peptides
in children with autism. Nutr Neurosci. 2004;7:151-161.
177. Vojdani A, Bazargan M, Vojdani E, et al. Heat shock
protein and gliadin peptide promote development of
peptidase antibodies in children with autism and patients
with autoimmune disease. Clin Diagn Lab Immunol.
2004;11:515-524.
178. Jyonouchi H, Sun S, Itokazu N. Innate immunity
associated with inflammatory responses and cytokine
production against common dietary proteins in patients
with autism spectrum disorder. Neuropsychobiology.
2002;46:76-84.
179. Ashwood P, Anthony A, Torrente F, et al. Spontaneous
mucosal lymphocyte cytokine profiles in children
with autism and gastrointestinal symptoms: mucosal
immune activation and reduced counter regulatory interleukin- 10. J Clin Immunol. 2004;24:664-673.
180. Afzal N, Murch S, Thirrupathy K, et al. Constipation
with acquired megarectum in children with autism. Pediatrics.
2003;112:939-942.
181. Barcia G, Posar A, Santucci M, et al. Autism and coeliac
disease. J Autism Dev Disord. 2008;38:407-408.
182. Lucarelli S, Frediani T, Zingoni AM, et al. Food allergy
and infantile autism. Panminerva Med. 1995;37:137-141.
183. Evangeliou A, Vlachonikolis I, Mihailidou H, et al.
Application of a ketogenic diet in children with autistic
behavior: pilot study. J Child Neurol. 2003;18:113-118.
184. O’Banion D, Armstrong B, Cummings RA, et al.
Disruptive behavior: a dietary approach. J Autism Child
Schizophr. 1978;8:325-337.
185. Sponheim E. [Gluten-free diet in infantile autism. A
therapeutic trial] [In Norwegian]. Tidsskr Nor Laegeforen.
1991;111:704-707.
186. Reichelt KL, Ekrem J, Scott H. Gluten, milk proteins
and autism: dietary intervention effects on behavior and
peptide secretion. J Appl Nutr. 1990;42:1-11.
187. Knivsberg AM, Wiig K, Lind G, et al. Dietary intervention
in autistic syndromes. Brain Dysfunction.
1990;3:315-327.
188. Knivsberg AM, Reichelt KL, Nodland M, et al. Autistic
symptoms and diet: a follow-up study. Scand J Ed
Research. 1995;39:223-236.
189. Whiteley P, Rodgers J, Savery D, et al. A gluten-free
diet as an intervention for autism and associated spectrum
disorders: preliminary findings. Autism. 1999;3:45.
190. Cade R, Privette M, Fregly M, et al. Autism and
schizophrenia: intestinal disorders. Nutritional Neuroscience.
2000;3:57-72.
191. Christison GW, Ivany K. Elimination diets in autism
spectrum disorders: any wheat amidst the chaff? J Dev
Behav Pediatr. 2006;27:S162-S171.
192. Goin-Kochel RP, Mackintosh VH, Myers BJ. Parental
reports on the efficacy of treatments and therapies for
their children with autism spectrum disorders. Research
in Autism Spectrum Disorders. 2009;3:528-537.
193. Knivsberg AM, Reichelt KL, Hoien T, et al. A randomised,
controlled study of dietary intervention in autistic
syndromes. Nutr Neurosci. 2002;5:251-261.
194. Elder JH, Shankar M, Shuster J, et al. The gluten-free,
casein-free diet in autism: results of a preliminary double
blind clinical trial. J Autism Dev Disord. 2006;36:413-420.
195. Millward C, Ferriter M, Calver S, et al. Gluten- and
casein-free diets for autistic spectrum disorder. Cochrane
Database Syst Rev. 2008;(2):CD003498.
196. Adams SJ, Burton N, Cutress A, et al. Development
of double blind gluten and casein free test foods for use
in an autism dietary trial. J Hum Nutr Diet. 2008;21:374.
197. Arnold GL, Hyman SL, Mooney RA, et al. Plasma
amino acids profiles in children with autism: potential
risk of nutritional deficiencies. J Autism Dev Disord.
2003;33:449-454.
198. Hediger ML, England LJ, Molloy CA, et al. Reduced
bone cortical thickness in boys with autism or autism
spectrum disorder. J Autism Dev Disord. 2008;38:848-856.
199. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic
activity in autism: abnormalities in the cerebral cortex and
basal forebrain. Am J Psychiatry. 2001;158:1058-1066.
200. Chez MG, Aimonovitch M, Buchanan T, et al. Treating
autistic spectrum disorders in children: utility of the
cholinesterase inhibitor rivastigmine tartrate. J Child
Neurol. 2004;19:165-169.
201. Hardan AY, Handen BL. A retrospective open trial of
adjunctive donepezil in children and adolescents with
autistic disorder. J Child Adolesc Psychopharmacol.
2002;12:237-241.
202. Chez MG, Nowinski CV, Buchanan CP. Donepezil
use in children with autistic spectrum disorders. Ann
Neurol. 2000;48:541.
203. Chez MG, Buchanan TM, Becker M, et al. Donepezil
hydrochloride: a double-blind study in autistic children.
J Pediatr Neurol. 2003;1:83-88.
204. Hertzman M. Galantamine in the treatment of adult
autism: a report of three clinical cases. Int J Psychiatry
Med. 2003;33:395-398.
205. Nicolson R, Craven-Thuss B, Smith J. A prospective,
open-label trial of galantamine in autistic disorder. J
Child Adolesc Psychopharmacol. 2006;16:621-629.
206. Niederhofer H, Staffen W, Mair A. Galantamine
may be effective in treating autistic disorder. BMJ.
2002;325:1422.
207. Campbell M, Anderson LT, Small AM, et al. Naltrexone
in autistic children: a double-blind and placebocontrolled
study. Psychopharmacol Bull. 1990;26:130-135.
208. Leboyer M, Bouvard MP, Launay JM, et al. Brief report:
a double-blind study of naltrexone in infantile autism.
J Autism Dev Disord. 1992;22:309-319.
209. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG,
et al. Placebo-controlled acute dosage naltrexone study
in young autistic children. Psychiatry Res. 1995;58:203-215.
210. Bouvard MP, Leboyer M, Launay JM, et al. Low-dose
naltrexone effects on plasma chemistries and clinical
symptoms in autism: a double-blind, placebo-controlled
study. Psychiatry Res. 1995;58:191-201.
211. Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone
in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc
Psychiatry. 1995;34:223-231.
212. Willemsen-Swinkels SH, Buitelaar JK, van Engeland
H. The effects of chronic naltrexone treatment in young
autistic children: a double-blind placebo-controlled
crossover study. Biol Psychiatry. 1996;39:1023-1031.
213. Elchaar GM, Maisch NM, Augusto LM, et al. Efficacy
and safety of naltrexone use in pediatric patients
with autistic disorder. Ann Pharmacother. 2006;40:1086-1095.
214. Koshes RJ, Rock NL. Use of clonidine for behavioral
control in an adult patient with autism. Am J Psychiatry.
1994;151:1714.
215. Ming X, Gordon E, Kang N, et al. Use of clonidine
in children with autism spectrum disorders. Brain Dev.
2008;30:454-460.
216. Fankhauser MP, Karumanchi VC, German ML, et al.
A double-blind, placebo-controlled study of the efficacy
of transdermal clonidine in autism. J Clin Psychiatry.
1992;53:77-82.
217. Jaselskis CA, Cook EH Jr, Fletcher KE, et al. Clonidine
treatment of hyperactive and impulsive children with autistic
disorder. J Clin Psychopharmacol. 1992;12:322-327.
218. Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine
treatment of hyperactivity and inattention in pervasive
developmental disorders: a retrospective analysis of 80
cases. J Child Adolesc Psychopharmacol. 2004;14:233-241.
219. Scahill L, Aman MG, McDougle CJ, et al. A prospective
open trial of guanfacine in children with pervasive
developmental disorders. J Child Adolesc Psychopharmacol.
2006;16:589-598.
220. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev
Behav Pediatr. 2008;29:303-308.
221. Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics
of a guanfacine extended-release formulation
in children and adolescents with attention-deficithyperactivity
disorder. Pharmacotherapy. 2007;27:1253-
1262.
222. Rossignol DA. Hyperbaric oxygen therapy might
improve certain pathophysiological findings in autism.
Med Hypotheses. 2007;68:1208-1227.
223. Rossignol DA, Rossignol LW. Hyperbaric oxygen
therapy may improve symptoms in autistic children.
Med Hypotheses. 2006;67:216-228.
224. Rossignol DA, Rossignol LW, James SJ, et al. The effects
of hyperbaric oxygen therapy on oxidative stress,
inflammation, and symptoms in children with autism:
an open-label pilot study. BMC Pediatr. 2007;7:36.
225. Chungpaibulpatana J, Sumpatanarax T, Thadakul
N, et al. Hyperbaric oxygen therapy in Thai autistic children.
J Med Assoc Thai. 2008;91:1232-1238.
226. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric
treatment for children with autism: a multicenter,
randomized, double-blind, controlled trial. BMC Pediatr.
2009;9:21.
227. Shenoy S, Arnold S, Chatila T. Response to steroid
therapy in autism secondary to autoimmune lymphoproliferative
syndrome. J Pediatr. 2000;136:682-687.
228. Stefanatos GA, Grover W, Geller E. Case study: corticosteroid
treatment of language regression in pervasive
developmental disorder. J Am Acad Child Adolesc Psychiatry.
1995;34:1107-1111.
229. Chez MG, Loeffel M, Buchanan C, et al. Pulse high
dose steroids as combination therapy with valproic acid
in epileptic aphasia patients with pervasive developmental
delay or autism. Ann Neurol. 1998;44:539.
230. Buitelaar JK, van Engeland H, de Kogel K, et al.
The adrenocorticotrophic hormone (4-9) analog ORG
2766 benefits autistic children: report on a second controlled
clinical trial. J Am Acad Child Adolesc Psychiatry.
1992;31:1149-1156.
231. Buitelaar JK, van Engeland H, de Kogel KH, et al.
The use of adrenocorticotrophic hormone (4-9) analog
ORG 2766 in autistic children: effects on the organization
of behavior. Biol Psychiatry. 1992;31:1119-1129.
232. Buitelaar JK, van Engeland H, van Ree JM, et al.
Behavioral effects of Org 2766, a synthetic analog of the
adrenocorticotrophic hormone (4-9), in 14 outpatient
autistic children. J Autism Dev Disord. 1990;20:467-478.
233. Boris M, Kaiser CC, Goldblatt A, et al. Effect of pioglitazone
treatment on behavioral symptoms in autistic
children. J Neuroinflammation. 2007;4:3.
234. Bradstreet JJ, Smith S, Granpeesheh D, et al. Spironolactone
might be a desirable immunologic and hormonal
intervention in autism spectrum disorders. Med
Hypotheses. 2007;68:979-987.
235. Gupta S, Rimland B, Shilling PD. Pentoxifylline:
brief review and rationale for its possible use in the treatment
of autism. J Child Neurol. 1996;11:501-504.
236. Heuer L, Ashwood P, Schauer J, et al. Reduced levels
of immunoglobulin in children with autism correlates
with behavioral symptoms. Autism Res. 2008;1:275-283.
237. Gupta S, Aggarwal S, Heads C. Dysregulated immune
system in children with autism: beneficial effects
of intravenous immune globulin on autistic characteristics.
J Autism Dev Disord. 1996;26:439-452.
238. Plioplys AV. Intravenous immunoglobulin treatment
of children with autism. J Child Neurol. 1998;13:79-82.
239. Gupta S. Immunological treatments for autism. J
Autism Dev Disord. 2000;30:475-479.
240. DelGiudice-Asch G, Simon L, Schmeidler J, et al.
Brief report: a pilot open clinical trial of intravenous immunoglobulin
in childhood autism. J Autism Dev Disord.
1999;29:157-160.
241. Plioplys AV. Intravenous immunoglobulin treatment
in autism. J Autism Dev Disord. 2000;30:73-74.
242. Boris M, Goldblatt A, Edelson SM. Improvement
in children with autism treated with intravenous gamma
globulin. J Nutritional Environmental Medicine.
2005;15:169-176.
243. Schneider CK, Melmed RD, Barstow LE, et al. Oral
human immunoglobulin for children with autism and
gastrointestinal dysfunction: a prospective, open-label
study. J Autism Dev Disord. 2006;36:1053-1064.
244. Handen BL, Melmed RD, Hansen RL, et al. A doubleblind,
placebo-controlled trial of oral human immunoglobulin
for gastrointestinal dysfunction in children with
autistic disorder. J Autism Dev Disord. 2009;39:796-805.
245. Stubbs EG, Budden SS, Burger DR, et al. Transfer
factor immunotherapy of an autistic child with congenital
cytomegalovirus. J Autism Dev Disord. 1980;10:451-458.
246. Fudenberg HH. Dialysable lymphocyte extract
(DLyE) in infantile onset autism: a pilot study. Biotherapy.
1996;9:143-147.
247. Bartz JA, Hollander E. Oxytocin and experimental
therapeutics in autism spectrum disorders. Prog Brain
Res. 2008;170:451-462.
248. Lerer E, Levi S, Salomon S, et al. Association between
the oxytocin receptor (OXTR) gene and autism:
relationship to Vineland Adaptive Behavior Scales and
cognition. Mol Psychiatry. 2008;13:980-988.
249. Wu S, Jia M, Ruan Y, et al. Positive association of the
oxytocin receptor gene (OXTR) with autism in the Chinese
Han population. Biol Psychiatry. 2005;58:74-77.
250. Jacob S, Brune CW, Carter CS, et al. Association
of the oxytocin receptor gene (OXTR) in Caucasian
children and adolescents with autism. Neurosci Lett.
2007;417:6-9.
251. Modahl C, Green L, Fein D, et al. Plasma oxytocin
levels in autistic children. Biol Psychiatry. 1998;43:270-
277.
252. Domes G, Heinrichs M, Michel A, et al. Oxytocin
improves “mind-reading” in humans. Biol Psychiatry.
2007;61:731-733.
253. Hollander E, Novotny S, Hanratty M, et al. Oxytocin
infusion reduces repetitive behaviors in adults with autistic
and Asperger’s disorders. Neuropsychopharmacology.
2003;28:193-198.
254. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases
retention of social cognition in autism. Biol Psychiatry.
2007;61:498-503.
255. Cohen DJ, Johnson WT, Caparulo BK. Pica and elevated
blood lead level in autistic and atypical children.
Am J Dis Child. 1976;130:47-48.
256. Accardo P, Whitman B, Caul J, et al. Autism and
plumbism. A possible association. Clin Pediatr (Phila).
1988;27:41-44.
257. Eppright TD, Sanfacon JA, Horwitz EA. Attention
deficit hyperactivity disorder, infantile autism, and elevated
blood-lead: a possible relationship. Mo Med.
1996;93:136-138.
258. Lidsky TI, Schneider JS. Autism and autistic symptoms
associated with childhood lead poisoning. Journal
of Applied Research. 2005;5:80-87.
259. Kidd PM. Autism, an extreme challenge to integrative
medicine. Part II: medical management. Alternative
Medicine Review. 2002;7:472-499.
260. Lonsdale D, Shamberger RJ, Audhya T. Treatment
of autism spectrum children with thiamine tetrahydrofurfuryl
disulfide: a pilot study. Neuro Endocrinol Lett.
2002;23:303-308.
261. Geier DA, Geier MR. A clinical trial of combined
anti-androgen and anti-heavy metal therapy in autistic
disorders. Neuro Endocrinol Lett. 2006;27:833-838.
262. Patel K, Curtis LT. A comprehensive approach
to treating autism and attention-deficit hyperactivity
disorder: a prepilot study. J Altern Complement Med.
2007;13:1091-1097.
263. Nataf R, Skorupka C, Amet L, et al. Porphyrinuria in
childhood autistic disorder: implications for environmental
toxicity. Toxicol Appl Pharmacol. 2006;214:99-108.
264. Bradstreet JJ, Geier DA, Kartzinel JJ, et al. A casecontrol
study of mercury burden in children with autistic
spectrum disorders. Journal of American Physicians and
Surgeons. 2003;8:76-79.
265. Soden SE, Lowry JA, Garrison CB, et al. 24-hour provoked
urine excretion test for heavy metals in children
with autism and typically developing controls, a pilot
study. Clin Toxicol (Phila). 2007;45:476-481.
266. Shannon M, Graef JW. Lead intoxication in children
with pervasive developmental disorders. J Toxicol Clin
Toxicol. 1996;34:177-181.
267. Geier DA, Geier MR. A prospective assessment of
porphyrins in autistic disorders: a potential marker for
heavy metal exposure. Neurotox Res. 2006;10:57-64.
268. Geier DA, Geier MR. A prospective study of mercury
toxicity biomarkers in autistic spectrum disorders.
J Toxicol Environ Health A. 2007;70:1723-1730.
269. Van der Linde AA, Pillen S, Gerrits GP, et al. Stevens-Johnson syndrome in a child with chronic mercury
exposure and 2,3-dimercaptopropane-1-sulfonate
(DMPS) therapy. Clin Toxicol (Phila). 2008;46:479-481.
270. Brown MJ, Willis T, Omalu B, et al. Deaths resulting
from hypocalcemia after administration of edetate disodium:
2003-2005. Pediatrics. 2006;118:e534-536.
271. Chen ZK, Lu ZQ. Sodium dimercaptopropane sulfonate
as antidote against non-metallic pesticides. Acta
Pharmacol Sin. 2004;25:534-544.
272. Flora SJ, Pande M, Mehta A. Beneficial effect of
combined administration of some naturally occurring
antioxidants (vitamins) and thiol chelators in the treatment
of chronic lead intoxication. Chem Biol Interact.
2003;145:267-280.
273. Flora SJ, Flora G, Saxena G, et al. Arsenic and lead
induced free radical generation and their reversibility
following chelation. Cell Mol Biol (Noisy-le-grand).
2007;53:26-47.
274. Rogan WJ, Dietrich KN, Ware JH, et al. The effect of
chelation therapy with succimer on neuropsychological
development in children exposed to lead. N Engl J Med.
2001;344:1421-1426.
275. Dietrich KN, Ware JH, Salganik M, et al. Effect of chelation
therapy on the neuropsychological and behavioral
development of lead-exposed children after school entry.
Pediatrics. 2004;114:19-26.
276. Bhattacharya A, Shukla R, Auyang ED, et al. Effect of
succimer chelation therapy on postural balance and gait
outcomes in children with early exposure to environmental
lead. Neurotoxicology. 2007;28:686-695.
277. Mitka M. Chelation therapy trials halted. JAMA.
2008;300:2236.
278. Gudarzi SS, Yasamy M, Akhondzadeh S. Cyproheptadine
in treatment of autism. Eur Psychiatry. 2002;17:230-231.
279. Akhondzadeh S, Erfani S, Mohammadi MR, et al.
Cyproheptadine in the treatment of autistic disorder: a
double-blind placebo-controlled trial. J Clin Pharm Ther.
2004;29:145-150.
280. Linday LA. Oral famotidine: a potential treatment for
children with autism. Med Hypotheses. 1997;48:381-386.
281. Linday LA, Tsiouris JA, Cohen IL, et al. Famotidine
treatment of children with autistic spectrum disorders:
pilot research using single subject research design. J Neural
Transm. 2001;108:593-611.
282. Purcell AE, Jeon OH, Zimmerman AW, et al. Postmortem
brain abnormalities of the glutamate neurotransmitter
system in autism. Neurology. 2001;57:1618-1628.
283. Moreno-Fuenmayor H, Borjas L, Arrieta A, et al.
Plasma excitatory amino acids in autism. Invest Clin.
1996;37:113-128.
284. Erickson CA, Chambers JE. Memantine for disruptive
behavior in autistic disorder. J Clin Psychiatry.
2006;67:1000.
285. Erickson CA, Posey DJ, Stigler KA, et al. A retrospective
study of memantine in children and adolescents
with pervasive developmental disorders. Psychopharmacology
(Berl). 2007;191:141-147.
286. Owley T, Salt J, Guter S, et al. A prospective, openlabel
trial of memantine in the treatment of cognitive,
behavioral, and memory dysfunction in pervasive developmental
disorders. J Child Adolesc Psychopharmacol.
2006;16:517-524.
287. Chez MG, Burton Q, Dowling T, et al. Memantine
as adjunctive therapy in children diagnosed with autistic
spectrum disorders: an observation of initial clinical
response and maintenance tolerability. J Child Neurol.
2007;22:574-579.
288. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett
syndrome. Neuropediatrics. 1993;24:339-340.
289. Mendhekar DN, Duggal HS. Acquired variant of
Rett’s disorder and response to lamotrigine. J Neuropsychiatry
Clin Neurosci. 2007;19:474-475.
290. Kumandas S, Caksen H, Ciftci A, et al. Lamotrigine in two cases of Rett syndrome. Brain Dev. 2001;23:240-242.
291. Stenbom Y, Tonnby B, Hagberg B. Lamotrigine in
Rett syndrome: treatment experience from a pilot study.
Eur Child Adolesc Psychiatry. 1998;7:49-52.
292. Uvebrant P, Bauziene R. Intractable epilepsy in
children. The efficacy of lamotrigine treatment, including
non-seizure-related benefits. Neuropediatrics.
1994;25:284-289.
293. Belsito KM, Law PA, Kirk KS, et al. Lamotrigine
therapy for autistic disorder: a randomized, doubleblind,
placebo-controlled trial. J Autism Dev Disord.
2001;31:175-181.
294. Posey DJ, Kem DL, Swiezy NB, et al. A pilot study
of D-cycloserine in subjects with autistic disorder. Am J
Psychiatry. 2004;161:2115-2117.
295. Sturmey P. Secretin is an ineffective treatment for
pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res Dev Disabil.
2005;26:87-97.
296. Esch BE, Carr JE. Secretin as a treatment for autism:
a review of the evidence. J Autism Dev Disord.
2004;34:543-556.
297. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin
for autism spectrum disorder. Cochrane Database
Syst Rev. 2005;(3):CD003495.
298. Ratliff-Schaub K, Carey T, Reeves GD, et al. Randomized
controlled trial of transdermal secretin on behavior
of children with autism. Autism. 2005;9:256-265.
299. Boso M, Emanuele E, Minazzi V, et al. Effect of longterm
interactive music therapy on behavior profile and
musical skills in young adults with severe autism. J Altern
Complement Med. 2007;13:709-712.
300. Kern P, Aldridge D. Using embedded music therapy
interventions to support outdoor play of young children
with autism in an inclusive community-based child care
program. J Music Ther. 2006;43:270-294.
301. Kim J, Wigram T, Gold C. The effects of improvisational
music therapy on joint attention behaviors in autistic
children: a randomized controlled study. J Autism
Dev Disord. 2008;38:1758-1766.
302. Corbett BA, Shickman K, Ferrer E. Brief report: the
effects of Tomatis sound therapy on language in children
with autism. J Autism Dev Disord. 2008;38:562-566.
303. Whipple J. Music in intervention for children and
adolescents with autism: a meta-analysis. J Music Ther.
2004;41:90-106.
304. Gold C, Wigram T, Elefant C. Music therapy for autistic
spectrum disorder. Cochrane Database Syst Rev.
2006;(2):CD004381.
305. Kaplan M, Carmody DP, Gaydos A. Postural orientation
modifications in autism in response to ambient
lenses. Child Psychiatry Hum Dev. 1996;27:81-91.
306. Kaplan M, Edelson SM, Seip JA. Behavioral changes
in autistic individuals as a result of wearing ambient
transitional prism lenses. Child Psychiatry Hum Dev.
1998;29:65-76.
307. Chen WX, Wu-Li L, Wong VC. Electroacupuncture
for children with autism spectrum disorder: pilot study of
2 cases. J Altern Complement Med. 2008;14:1057-1065.
308. Allam H, ElDine NG, Helmy G. Scalp acupuncture effect
on language development in children with autism: a
pilot study. J Altern Complement Med. 2008;14:109-114.
309. Rimland B, Edelson SM. Brief report: a pilot study
of auditory integration training in autism. J Autism Dev
Disord. 1995;25:61-70.
310. Sinha Y, Silove N, Wheeler D, et al. Auditory integration
training and other sound therapies for autism
spectrum disorders: a systematic review. Arch Dis Child.
2006;91:1018-1022.
311. Cullen-Powell LA, Barlow JH, Cushway D. Exploring
a massage intervention for parents and their children
with autism: the implications for bonding and attachment.
J Child Health Care. 2005;9:245-255.
312. Williams TI. Evaluating effects of aromatherapy
massage on sleep in children with autism: a pilot study.
Evid Based Complement Alternat Med. 2006;3:373-377.
313. Escalona A, Field T, Singer-Strunck R, et al. Brief
report: improvements in the behavior of children with
autism following massage therapy. J Autism Dev Disord.
2001;31:513-516.
314. Silva LM, Cignolini A. A medical qigong methodology
for early intervention in autism spectrum disorder: a
case series. Am J Chin Med. 2005;33:315-327.
315. Silva LM, Ayres R, Schalock M. Outcomes of a
pilot training program in a qigong massage intervention
for young children with autism. Am J Occup Ther.
2008;62:538-546.
316. Silva LM, Cignolini A, Warren R, et al. Improvement
in sensory impairment and social interaction in
young children with autism following treatment with an
original Qigong massage methodology. Am J Chin Med.
2007;35:393-406.
317. Jarusiewicz B. Efficacy of neurofeedback for children
in the autism spectrum: a pilot study. J Neurotherapy.
2002;6:39-49.
318. Robinson TW. Homeopathic secretin in autism:
a clinical pilot study. British Homeopathic Journal.
2001;90:86-91.
319. Warwick TC, Griffith J, Reyes B, et al. Effects of vagus
nerve stimulation in a patient with temporal lobe epilepsy
and Asperger syndrome: case report and review of
the literature. Epilepsy Behav. 2007;10:344-347.
320. Park YD. The effects of vagus nerve stimulation
therapy on patients with intractable seizures and either
Landau-Kleffner syndrome or autism. Epilepsy Behav.
2003;4:286-290.
321. Danielsson S, Viggedal G, Gillberg C, et al. Lack of
effects of vagus nerve stimulation on drug-resistant epilepsy
in eight pediatric patients with autism spectrum
disorders: a prospective 2-year follow-up study. Epilepsy
Behav. 2008;12:298-304.